News
Public · Published
Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November
Pharming Group reported third quarter 2026 results, with RUCONEST revenue up 14% to $93.8 million and Joenja revenue up 58% to $23.8 million. Total revenue grew 21% and operating profit rose 89%, supported by launches in Germany and Japan.
Published:
Updated:
What happened
Pharming Group reported third quarter 2026 results, with RUCONEST revenue up 14% to $93.8 million and Joenja revenue up 58% to $23.8 million. Total revenue grew 21% and operating profit rose 89%, supported by launches in Germany and Japan.
Confirmed
Global impact / market context
Faster sales of both main drugs mean more cash coming in, which Pharming says it can use to fund research and new launches while staying disciplined. Higher revenue and profit also help the company absorb the costs of expanding Joenja into new countries and patient groups.
Analyst inference
Investors often judge biotech firms by whether their existing medicines keep growing, because that growth funds future trials. Pharming frames this quarter as beating market expectations, but it is unaudited and preliminary, so the figures could still change before final reporting.
Analyst inference
What to watch
- Pharming says topline Phase II data for leniolisib beyond APDS will arrive in November, which means early results testing the drug in other diseases; watch whether the data support further development spending. Confirmed
- Watch U.S. shipments of newly approved Joenja doses for children aged 4 to 11 above 27 kg, which the company says begin after quarter end; uptake would show whether this expands the patient base. Proposed
- Monitor whether RUCONEST revenue growth holds as U.S. demand stabilizes, since this drug is the larger revenue source and slower growth would reduce cash available for Joenja launches and research. Analyst inference